Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease. Founded in 1958 and spun off from Baxter International in 2000, the company pioneered the first commercially available artificial heart valve. Today, Edwards Lifesciences derives the majority of its revenue from its Transcatheter Aortic Valve Replacement (TAVR) products, which allow for minimally invasive heart valve replacement. The company's other key business segments include Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart solutions (featuring premium tissue valves like the RESILIA portfolio), and Implantable Heart Failure Management (IHFM). In September 2024, Edwards completed the sale of its Critical Care product group to Becton Dickinson (BD) for $4.2 billion to focus exclusively on its core structural heart innovations. Operating globally, the company maintains manufacturing facilities in the United States, Costa Rica, Ireland, and Singapore, and distributes its cardiovascular devices to hospitals and healthcare providers worldwide. Edwards maintains a dominant competitive position in the TAVR market, supported by extensive clinical evidence and a robust pipeline of next-generation transcatheter technologies.
